



PRIVATE FUNDING OPPORTUNITIES: FEB 17, 2017

Please contact Corporate & Foundation Relations in the Office of Development at devcfr@mg.harvard.edu if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

Please note that any grant that brings in less than **15% in indirect costs (IDC)** will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submission of the award.

1. International Research Grant Program: Alzheimer's Association Clinical Fellowship to Promote Diversity (AACF-D) Program, Alzheimer's Association (ALZ)

The Fellowship to Promote Diversity is intended to support exceptional clinical fellows who are currently underrepresented at academic institutions in clinical research training in Alzheimer's and related dementias. For the purpose of this fellowship, clinical research is defined as patient-oriented research conducted with human subjects, or translational research specifically designed to develop treatments or enhance diagnosis of neurological disease. These areas of research include epidemiologic or behavioral studies, clinical trials, studies of disease mechanisms, the development of new technologies, and health services and outcomes research." Disease related studies not directly involving humans or human tissue are also encouraged if the primary goal is the development of therapies, diagnostic tests, or other tools to prevent or mitigate neurological diseases.

Areas of focus are high priority research areas in which the Association actively seeks proposals. The areas are defined broadly, and the examples cited are not intended to preclude or constrain other projects or proposals. Potential applicants are strongly encouraged to submit proposals in their own areas of interest or formulate questions different from those presented in this announcement. Innovative and novel ideas to address challenges in research are the core of the Association's scientific program.

1. Research in Diverse Populations: Closing the Gap
2. Social and behavioral research has the potential to increase our understanding of the effects of Alzheimer's disease and other dementias on individuals with the disease, their families and other caregivers. At the same time, it can increase our knowledge about interventions that improve care practices, health, functional and emotional outcomes and quality of life, as well as prevent or reduce symptoms for millions of individuals and their families.



Do you want to learn more about identifying external funding opportunities? See [ECOR's website](#) for information on the funding opps database, **COS Pivot** or contact Amy Robb <arobb@mg.harvard.edu> to schedule an individual consultation or group training session.

3. Biological Focus: Causes, Early Detection, Treatment, Models, Prevention and Risk Factors.

Award Amount: \$175,000 paid over paid over 2-3 years

Indirect Costs: 10%

LOI Deadline: Mar 1, 2017

Website: http://www.alz.org/research/alzheimers_grants/types_of_grants.asp

2. International Research Grant: Alzheimer's Association Research Grant to Promote Diversity (AARG-D), Alzheimer's Association (ALZ)

The grant is awarded to investigators who are currently underrepresented at academic institutions in Alzheimer's or related dementias research. The objective of this award is to increase the number of highly trained investigators from diverse backgrounds whose basic, clinical and social/behavioral research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to Alzheimer's and related dementias in general and in health disparities populations.

The purpose of this program is to provide underrepresented new investigators with funding that will allow them to develop preliminary or pilot data, to test procedures, and to develop hypotheses. The intent is to support early-career development that will lay the groundwork for future research grant applications to the National Institutes of Health, National Science Foundation and other funding agencies and groups, including future proposals to the Association.

Areas of focus are high priority research areas in which the Association actively seeks proposals. The areas are defined broadly, and the examples cited are not intended to preclude or constrain other projects or proposals. Potential applicants are strongly encouraged to submit proposals in their own areas of interest or formulate questions different from those presented in this announcement. Innovative and novel ideas to address challenges in research are the core of the Association's scientific program.

Award Amount: \$150,000 paid over 2-3 years

Indirect Costs: 10%

LOI Deadline: Mar 1, 2017

Website: http://www.alz.org/research/alzheimers_grants/types_of_grants.asp

3. International Research Grant Program: Alzheimer's Association Clinical Fellowship (AACF), Alzheimer's Association (ALZ)

The Association recognizes the need to support clinical research training in Alzheimer's and related dementias. For the purpose of this fellowship, clinical research is defined as patient-oriented research conducted with human subjects, or translational research specifically

designed to develop treatments or enhance diagnosis of neurological disease. These areas of research include epidemiologic or behavioral studies, clinical trials, studies of disease mechanisms, the development of new technologies, and health services and outcomes research." Disease related studies not directly involving humans or human tissue are also encouraged if the primary goal is the development of therapies, diagnostic tests, or other tools to prevent or mitigate neurological diseases.

Areas of focus are high priority research areas in which the Association actively seeks proposals. The areas are defined broadly, and the examples cited are not intended to preclude or constrain other projects or proposals. Potential applicants are strongly encouraged to submit proposals in their own areas of interest or formulate questions different from those presented in this announcement. Innovative and novel ideas to address challenges in research are the core of the Association's scientific program.

Award Amount: \$175,000 paid over 2-3 years

Indirect Costs: 10%

LOI Deadline: Mar 1, 2017

Website: http://www.alz.org/research/alzheimers_grants/types_of_grants.asp

4. International Research Grant Program: Alzheimer's Association Research Grant (AARG), Alzheimer's Association (ALZ)

The Alzheimer's Association Research Grant aims to fund investigators who are less than 10 years past their doctoral or post residency (MD or DO) or investigators that are new to Alzheimer's and related dementia field of research even if past the 10 years.

The purpose of this program is to provide newly independent investigators with funding that will allow them to develop preliminary or pilot data, to test procedures and to develop hypotheses. The intent is to support early-career development that will lay the groundwork for future research grant applications to the National Institutes of Health, National Science Foundation and other funding agencies and groups, including future proposals to the Alzheimer's Association. All NIRG applications must target defined areas of focus for fiscal year 2017 to be considered responsive to the program announcement.

Areas of focus are high priority research areas in which the Association actively seeks proposals. The areas are defined broadly, and the examples cited are not intended to preclude or constrain other projects or proposals. Potential applicants are strongly encouraged to submit proposals in their own areas of interest or formulate questions different from those presented in this announcement. Innovative and novel ideas to address challenges in research are the core of the Association's scientific program.

Award Amount: \$150,000 paid over 2-3 years

Indirect Costs: 10%

LOI Deadline: Mar 1, 2017

Website: http://www.alz.org/research/alzheimers_grants/types_of_grants.asp

5. GlaxoSmithKline Distinguished Scholar in Respiratory Health, American College of Chest Physicians (ACCP)/CHEST Foundation

In 2000, this grant was established as a benchmark for clinical innovations that would translate into healthier patient lives. The scholar is expected to complete an investigative project that has significant impact on respiratory health in the clinical, translational, and/or population health arenas. The scholar is encouraged but not required to take advantage of the extensive resources of CHEST, such as the following: (1) collaborations with leaders in the CHEST Airways Disorders NetWork or various steering committees; (2) CHEST educational material; or (3) CHEST simulation resources.

The scholar will have a 3-year opportunity to examine issues that relate to patients with respiratory disease. The grant is intended to permit the investigation of issues that are not easily supported by traditional, shorter-term funding opportunities.

Applications must address research that: (1) enhances scientific knowledge, advances evidence-based medicine, and/or improves clinical/community practice related to respiratory health patients; (2) furthers the understanding of the mechanism and management of acute and life-threatening respiratory illness; or (3) addresses the organizational attributes associated with the optimal delivery of respiratory health services.

The project is expected to be a higher-level translational research project (T1-T5; for definitions please see: <https://ctsi.mcw.edu/images/CTSI-Translational-Continuum.pdf>).

Award Amount: \$150,000 paid over 3 years

Indirect Costs: None

Application Deadline: Mar 31, 2017

Website: <https://foundation.chestnet.org/grants/apply-for-a-grant/>

6. CHEST Foundation Research Grant in Lung Cancer, American College of Chest Physicians (ACCP)/CHEST Foundation

Applications must address research that leads to improved medical and/or surgical detection, treatment, and/or cure of lung cancer. Higher-level translational research project preferred (T1-T5); basic (cellular or animal) research projects will not be considered.

Award Amount: Up to \$200,000 paid over 2 years

Indirect Costs: None

Application Deadline: Mar 31, 2017

Website: <https://foundation.chestnet.org/grants/apply-for-a-grant/>

7. CHEST Foundation Research Grant in Pulmonary Fibrosis, American College of Chest Physicians (ACCP)/CHEST Foundation

Applications must contribute to the effective treatment, management, or cure for pulmonary fibrosis. Higher-level translational research project preferred (T1-T5); basic (cellular or animal) research projects will not be considered.

This grant is supported by Boehringer Ingelheim Pharmaceuticals, Inc.

Award Amount: \$50,000 for 1 year

Indirect Costs: None

Application Deadline: Mar 31, 2017

Website: <https://foundation.chestnet.org/grants/apply-for-a-grant/>

8. CHEST Foundation Research Grant in Chronic Obstructive Pulmonary Disease, American College of Chest Physicians (ACCP)/CHEST Foundation

Applications must address clinical, population, or community engagement/health services aspects of COPD with relevance to the prevention and/or reduction in morbidity or mortality associated with COPD. Higher-level translational research project preferred (T1-T5); basic (cellular or animal) research projects will not be considered. This grant is supported by AstraZeneca LP.

Award Amount: \$50,000 for 1 year

Indirect Costs: None

Application Deadline: Mar 31, 2017

Website: <https://foundation.chestnet.org/grants/apply-for-a-grant/>

9. Pilot and Feasibility Awards, Cystic Fibrosis Foundation (CFF)

These grants are offered to support projects that will develop and test new hypotheses and/or new methods (or those being applied to the problems of CF for the first time), and to support promising new investigators as they establish themselves in research areas relevant to CF. The intent of these awards is to enable investigators to collect sufficient data to compete successfully for support from the NIH or other funding agencies. Special consideration will be given to those projects that propose innovative and creative approaches to the problems of cystic fibrosis. Applications for continued funding of the same project, or for long-term support of an investigator, will not be considered.

Pilot and Feasibility Grant applications should focus on basic science research. Those proposals that include methodologies requiring sampling of materials from human subjects will be considered under this mechanism only if the sampling method constitutes minimal patient risk (e.g., venipuncture) and the sample will be utilized in bench research.

While CFTR biogenesis, trafficking, structure/function, airway defense, and microbial adaptation to the CF lung remain relevant, CFF is interested in funding new areas of research that may lead to the development of new and innovative therapies. Investigators working in these areas are encouraged to submit an application for consideration.

Emerging research interests:

1. Influence of CFTR modulation on the airway milieu in patients, animal models, and in vitro
2. studies, including resident pathogens, inflammation, mucin structure (tethered and secreted),
3. airway surface liquid (ASL), and mucociliary clearance
4. Effect of CFTR activity on lung inflammation and inflammatory cell function
5. Relationship between killing and clearance (mechanical and phagocytic) of inhaled bacteria and
6. the impact upon inflammatory signaling
7. Molecular characterization of CFTR mutations other than F508del
8. Novel means for restoring CFTR function
 - a. Gene editing/repair strategies
 - b. Delivery methods for gene, RNA, and protein to the lung and other affected tissues
 - c. Cellular targets for CFTR correction
 - i. Lung progenitor cells, airway stem cell niche
 - ii. Induced pluripotent stem cells (iPSC)

Funding priority will be placed on those projects that will lead to a better understanding of disease mechanisms, pathophysiology, and prevention strategies.

Award Amount: \$108,000 paid over 2 years

Indirect Costs: 8%

Application Deadline: Apr 19, 2017

Website: <https://www.cff.org/Our-Research/For-Researchers/Research-Grants/Pilot-and-Feasibility-Awards/>

10. CFF/NIH-Unfunded Grant Award, Cystic Fibrosis Foundation (CFF)

The objective of this award is to support excellent CF-related research projects that have been submitted to and approved by the National Institutes of Health, but cannot be supported by available NIH funds.

Support from the Foundation is intended to provide for the development of sufficient preliminary data to make CF-related grant applications highly competitive in the NIH review process. However, as a result of funding constraints on the NIH, coupled with the growing

interest in CF research, occasions arise in which highly meritorious grant applications are submitted to the NIH but are not funded.

Applications must have been submitted as an R01/R21 and fall within the upper 40th percentile.

The majority of morbidity and mortality associated with cystic fibrosis (CF) today is due to lung disease. In CF, innate defenses are compromised and inhaled or aspirated pathogens are able to establish chronic infections. CF is unique in that only a small subset of pathogens have been linked to disease progression, and the infection remains, for the most part, compartmentalized. Unfortunately, the neutrophil dominant inflammatory response causes tissue destruction and compromised organ- level function. Both the host and pathogen adapt as the initial insult evolves into an indolent, chronic infection punctuated by acute exacerbations.

Kalydec (VX- 770), the first drug to target the basic CF TR defect, demonstrated that CFTR modulating drugs improve clinical parameters such as sweat chloride, lung function, and body weight. CFF will continue to support efforts that improve our understanding of basic defects as well as mechanisms by which CFTR modulators improve patient outcomes. While CFTR biogenesis, trafficking, structure/function, airway defense, and microbial adaption to the CF lung remain relevant, CFF is interested in funding new areas of research that may lead to the development of new and innovative therapies. Investigators working in these areas are encouraged to submit applications for consideration.

Emerging research interests:

1. Influence of CFTR modulation on the airway milieu in patients, animal models, and in vitro studies, including resident pathogens, inflammation, mucin structure (tethered and secreted), and mucociliary clearance
2. Effect of CFTR activity on lung inflammation and inflammatory cell function
3. Relationship between killing and clearance (mechanical and phagocytic) of inhaled bacteria and the impact upon inflammatory signaling
4. Molecular characterization of CFTR mutations other than F508del
5. Novel means for restoring CFTR function such as:
 - a. Gene editing/repair strategies
 - b. Delivery methods for gene, RNA, and protein to the lung and other affected tissues
 - c. Cellular targets for CFTR correction
 - i. Lung progenitor cells, airway stem cell niche
 - ii. Induced pluripotent stem cells (iPSC)

Funding priority will be placed on those projects that will lead to a better understanding of disease mechanisms, pathophysiology, and prevention strategies.

Award Amount: Up to \$250,000 paid over 2 years

Indirect Costs: None

Proposal Deadline: Oct 31, 2017

Website: <https://www.cff.org/Research/Researcher-Resources/Awards-and-Grants/Research-Awards/CFF-NIH-Unfunded-Grant-Award/>

11. Jacobs Foundation Research Fellowship Program - Jacobs Early Career Research Fellowship, Jacobs Foundation

The Foundation Research Fellowship Program is a globally competitive fellowship program for early and mid-career researchers aiming at improving the development and living conditions of children and youth or contributing to one of the Jacobs Foundation's thematic priorities. This includes, but is not limited to educational sciences, psychology, economics, sociology, family studies, media studies, political sciences, linguistics, neurosciences, and medical sciences.

Fellowships are awarded to the most highly talented and innovative young scholars and mid-career researchers working on child and youth development.

Scholars who engage in interdisciplinary work on individual development and learning of children and youth, and who seek to combine genetic, epigenetic, neurobiological, behavioral and social levels of analysis, are particularly encouraged to apply.

Besides providing Fellows with independent and competitive funding, the program offers a wide range of non-financial benefits. Fellows are encouraged to interact with each other and make use of the Jacobs Foundation's Conference Center Marbach Castle at Lake Constance (Germany) for short-term group residencies and workshops. Networking and alumni events will enrich the fellowships

Award Amount: Fr150,000 CHF paid over 3 years

Indirect Costs: 10%

Pre-Application Deadline: Mar 31, 2017

Website: <http://jacobsfoundation.org/what-we-do/research-funding/jacobs-research-fellowship-program/>

12. Jacobs Foundation Research Fellowship Program - Jacobs Advanced Research Fellowship, Jacobs Foundation

The Jacobs Foundation has announced the inaugural call for applications for its Research Fellowship Program. The Jacobs Foundation Research Fellowship Program is an internationally open, competitive fellowship program for early and mid-career researchers focusing on child and youth development.

Fellowships are awarded to the most highly talented and innovative young scholars and mid-career researchers working on child and youth development. Funds from Jacobs Foundation Research Fellowships are awarded directly to the Fellow's institution and may be used over a

three-year period to partially cover the Fellow's salary and for any activity supporting the Fellow's research, such as assistant salaries, equipment, technical assistance, professional travel, or trainee support.

Fellows are selected on the basis of their research accomplishments, creativity, and potential to become leaders in the scientific community through their contributions to the field of child and youth development. International relevance of the fellow's planned work, the alignment of planned projects with the goals of the Jacobs Foundation, and the willingness to identify with our aims and to engage actively with us will also be selection criteria.

Award Amount: Fr 400,000 CHF paid over 3 years

Indirect Costs: 10%

Pre-Application Deadline: Mar 31, 2017

Website: <http://jacobsfoundation.org/what-we-do/research-funding/jacobs-research-fellowship-program/>

13. Research Grants, Morton Cure Paralysis Fund (MCPF)

The Morton Cure Paralysis Fund (MCPF) is committed to developing effective therapies (cures) for paralysis associated with spinal cord injury and other disorders of the central nervous system (CNS).

MCPF funds activities that hold promise of identifying therapies (cures) for paralysis in humans. MCPF has particular focus of placing projects in the research pipeline, that is, enabling scientists to develop the proof concept data necessary to apply for larger NIH grants. The development of effective therapies for chronic injury is a high priority for the organization. Basic research will be supported if it has clear potential to accelerate progress at the applied end of the continuum and/or if it reflects innovative research or a 'change of direction.'

The focus areas are:

1. Understanding the effects of spinal cord injury at the cellular level, particularly with emphasis on that which determines apoptosis and/or prohibits regrowth. As stated above, if the proposed project is at this level, it is important that the proposal demonstrate how the project is a change of direction, innovative research or can be quickly moved to therapeutic application.
2. Studying strategies to promote neuronal growth and survival, encourage the formation of synapses, enhance the production of myelin, restore conduction capabilities, or otherwise lead to restoration of the compromised circuitry in the acutely and chronically injured CNS.
3. Evaluating new therapies in clinical trial.

In addition to those elements listed above, MCPF will also take into account projects that:

- Encourage promising new investigators to undertake research on regeneration and recovery, particularly with respect to the spinal cord;
- Encourage researchers who are well-established in other areas to transfer their efforts to spinal cord research; and,
- Enable researchers with novel ideas to test their ideas and develop pilot data for seeking larger awards from NIH and other funding sources.

Award Amount: Up to \$75,000 for 1-2 years

Indirect Costs: Unpublished

Application Deadline: Apr 30, 2017

Website: <http://www.mcpf.org/Pages/Resources.aspx?Grants=Y>

14. Large Grants for Research on Gambling Disorders, National Center for Responsible Gaming (NCRG)

The Large Grants program provides support for discrete, specified, circumscribed research projects related to gambling disorders.

Award Amount: \$150,000 paid over 2 years

Indirect Costs: 15%

LOI Deadline: Jun 1, 2017

Website: <http://www.ncrg.org/research-center/apply-ncrg-funding-0>

15. Independent Grants for Learning & Change (IGL&C): Track 2 - Call for Grant Applications - Emerging Therapies in Inflammatory Bowel Disease (IBD), Pfizer, Inc. New

The mission of Pfizer Independent Grants for Learning & Change (IGL&C) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. "Independent" means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

Through this CGA Pfizer encourages organizations to submit grant requests that, if funded, will support education in a specific disease state, therapeutic area, or broader area of educational need.

Specific Area of Interest for this CGA: The intent of this CGA is to encourage organizations to design education programs to reach gastroenterologists' and gastroenterology fellows', nurse practitioners, physician assistants, and all other healthcare professionals involved in the care and treatment of adult patients with inflammatory bowel disease (IBD).

As research has progressed into the pathogenesis of the IBD spectrum, new therapeutic targets and strategies have been discovered. Programs aimed at increasing awareness and understanding of emerging therapies in the treatment of adult patients with IBD will be considered.

Programs with the highest likelihood of improving the health care team's understanding of emerging therapies as well as a large reach in the treatment of inflammatory bowel disease will be given the highest priority.

Award Amount: \$200,000

Indirect Costs: 28%

Application Deadline: Feb 24, 2017

Website: http://www.pfizer.com/responsibility/grants_contributions/grants_process

16. Independent Grants for Learning & Change (IGL&C): Track 2 - Call for Grant Applications (CGA) - Advanced or Metastatic Breast Cancer Treatment: Real World CDK 4/6 Inhibition Therapy Management in the Clinical Practice Team, Pfizer, Inc. New

The mission of Pfizer Independent Grants for Learning & Change (IGL&C) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. "Independent" means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

Through this CGA Pfizer encourages organizations to submit grant requests that, if funded, will support education in a specific disease state, therapeutic area, or broader area of educational need. Educational activities should not be focused on products specific to Pfizer.

Specific Area of Interest for this CGA: It is our intent to support continuing professional development programs (CE/CME) for allied health professionals (nurses, nurse practitioners, physician assistants, medical technicians, etc.) involved in the care and management of patients with advanced or metastatic breast cancer.

All members of the clinical practice team play an important role in counseling and supporting patients during therapy, including explaining possible benefits and side effects of different treatments and answering patient questions.

Proposed continuing education programs should increase the awareness and understanding of the management of patients with advanced or metastatic breast cancer using CDK 4/6 inhibitors. Possible areas of focus could include:

- Improving provider/patient communication regarding treatment options, treatment initiation, and management

- Understanding how patient adherence is monitored and addressed
- Increasing awareness and understanding of how dose adjustments are implemented in both the clinical trial and real world setting
- Understanding the role a nurse navigator plays in the management of these patients

All activity types will be considered through this CGA, including live events, satellite symposia, workshops, online courses, print materials, and other enduring materials including published proceedings. Efforts should be made to encourage interaction, incorporate real-world patient case discussions, and provide opportunities to extend and reinforce learning opportunities beyond the live setting.

Award Amount: \$500,000 paid over 2 years

Indirect Costs: 28%

Application Deadline: Mar 22, 2017

Website: http://www.pfizer.com/responsibility/grants_contributions/grants_process

17. ASPIRE Rheumatology, Dermatology and Inflammatory Bowel Disease Research Awards, Pfizer, Inc./Advancing Science through Pfizer - Investigator Research Exchange (ASPIRE Research Awards)

This ASPIRE program is part of Pfizer's commitment to supporting research in autoimmune diseases within rheumatology and dermatology. The mission of the ASPIRE program is to fund high quality basic science, translational and clinical research through a competitive grants program that advances medical knowledge in the epidemiology, pathogenesis and treatment of selected diseases.

Scientific research continues to advance our knowledge and understanding of autoimmune diseases within rheumatology and dermatology. The 2015 ASPIRE Rheumatology and Dermatology Research Awards will fund meritorious research proposals focusing on rheumatoid arthritis and plaque psoriasis that have the potential to improve patient care.

Research areas of interest in rheumatoid arthritis and plaque psoriasis are as follows:

1. General

- Approaches to improving communication and dialog between patients and health care providers. Examples include enduring materials, technological advancements, or web-based teaching programs.
- Health economic and outcomes research related to autoimmune diseases

2. Rheumatoid Arthritis

- Use of biomarkers of any type in assessment and management
- Use of ultrasound and magnetic resonance imaging in assessment and management

- Comorbid conditions, e.g., cardiovascular risk, ophthalmologic risk, risk of diabetes, increased risks with concomitant therapies (epidemiology, overlapping pathogenesis, assessment and management of these conditions in rheumatoid arthritis patients)
- Approaches to improving adherence to therapy
- Approaches to improving management (e.g. treating to a specific goal or target by monitoring response and adjusting therapy as needed; evidence-based treatment algorithms; factors predictive of response to therapy)
- Signaling pathways implicated in pathogenesis
- Research related to kinase inhibitors and other small molecules in treatment, which are not being studied currently by a company competing with Pfizer, Inc.

3. Plaque Psoriasis

- Genomic research to improve understanding of the heterogeneity of disease (for example, differences between "early" onset and "late" onset)
- Signaling pathways implicated in pathogenesis
- Factors that contribute to differences in physician and patient ratings of severity
- Approaches to improving adherence to therapy
- Comorbid conditions (epidemiology, overlapping pathogenesis, assessment and management of these conditions in plaque psoriasis patients)
- Approaches to improving management (e.g. treating to a specific goal or target by monitoring response and adjusting therapy as needed; treatment algorithms)

Hypothesis-testing research is preferred. Uncontrolled pilot and exploratory studies will be considered if reasonably hypothesis-generating. It is expected that the findings will be suitable for presentation at a medical or scientific congress and/or publication in a peer-reviewed journal, and will be submitted to one or both. Proposed studies therefore need to show adequate statistical rigor (for designs with control groups), or be sized for scientific credibility (observational designs).

Award Amount: \$150,000 paid over 2 years

Indirect Costs: 28%

Application Deadline: Mar 17, 2017

Website: <https://www.aspireresearch.org/Rheumatology/index.html>

18. ASPIRE Awards in Hemophilia Research, Pfizer, Inc./Advancing Science through Pfizer - Investigator Research Exchange (ASPIRE Research Awards)

As competition for research funding increases, the ASPIRE Hemophilia program underscores Pfizer's commitment to supporting investigators with an interest in advancing their academic research careers in Hemophilia A and B. The mission of the ASPIRE Program is as follows: (1) to support basic science, translational and clinical research through a competitive grants program that advances medical knowledge in the pathogenesis and treatment of hemophilia; and (2) to

support academic research as well as the career development of promising young and established scientists.

Basic science and clinical research continue to advance our knowledge and understanding of Hemophilia A and Hemophilia B. However, the clinical applicability of these findings is not always apparent and correlative studies may not be readily available.

The ASPIRE Hemophilia program is designed to support basic science and clinical research in Hemophilia pathogenesis, risk factors, host response and clinical outcomes in Hemophilia A and/or Hemophilia B as well as translation of the resulting knowledge to bridge the gap between bench and bedside. It is hoped that the results will lead to a better understanding of disease mechanisms and treatment options to enhance the clinical care of patients with Hemophilia A or Hemophilia B.

Applicants should consider the following components when developing their research proposals: in vitro, in vivo and clinical investigations; evaluation of disease pathogenesis and host response; and comparison of host response and clinical impact.

The following topics fall outside of the scope of the ASPIRE Hemophilia Research Program: general education and/or training; public health; support for ongoing clinical programs that are part of an organization's routine operations; and proposals that do not evaluate Hemophilia A or Hemophilia B.

Projects are expected to yield results that will advance the medical knowledge of Hemophilia A or Hemophilia B. It is expected that results will be presented at scientific meetings and published in peer-reviewed journals.

Both drug and non-drug proposals will be considered for funding.

Award Amount: Up to \$200,000 paid over 1-2 years

Indirect Costs: 28%

Application Deadline: Mar 31, 2017

Website: <https://www.aspireresearch.org/ASPIRE-Hemophilia/index.html>

19. Research Grants, Shwachman-Diamond Syndrome Foundation (SDSF)

Shwachman-Diamond Syndrome (SDS) is a multi-system autosomal-recessive disorder characterized by exocrine pancreatic dysfunction, and varying degrees of marrow dysfunction with cytopenias. Many associated clinical problems have also been described, including skeletal anomalies, metaphyseal dysostosis, rib abnormalities, cleft palate, dental abnormalities and others. SDSF is an organization actively helping the victims of this disease. SDSF is accepting grant requests for research relevant to this disease.

Any high quality, innovative research proposal deemed relevant to SDS will be considered. The following are areas of particular interest:

- Investigate or evaluate potential novel therapies or potential novel therapeutic strategies- preferred applications
- Evaluate predictors of bone marrow abnormalities to determine their correlation with the disease
- Determine the causes of and investigate treatments for bone marrow failure and leukemia
- Evaluate protocols and regimens for bone marrow transplants Evaluate causes and investigate treatments for graft vs host disease and other infections of post bone marrow transplants
- Investigations related to adult patient presentation, management, and care including transition from pediatric-centered to adult care

Award Amount: \$70,000 paid over 2 years

Indirect Costs: 10%

Application Deadline: May 15, 2017

Website: <http://www.shwachman-diamond.org/grant-application/>